Physician profile
Tabitha Davidson
NPI 1003089129
$2,390.54
in general payments reported to CMS, 2019-2025
15 companies · $71.51 in 2025
The $71.51 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $662 · 2022: $1,001 · 2023: $561 · 2024: $94.13 · 2025: $71.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,200.88 | 2021-2023 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $698.77 | 2021-2025 | |
| Janssen Biotech, INC. | $160.44 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.39 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $54.12 | 2021-2022 | |
| Gilead Sciences, INC. | $34.09 | 2021-2022 | |
| Ardelyx, INC. | $29.14 | 2022-2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $24.68 | 2021 | |
| Daiichi Sankyo INC. | $23.32 | 2022 | |
| Intercept Pharmaceuticals, INC. | $15.30 | 2022 | |
| Braintree Laboratories, INC. | $14.68 | 2022 | |
| Merck Sharp & Dohme LLC | $14.43 | 2021 | |
| Saluda Medical Americas, INC. | $14.04 | 2025 | Evoke |
| Pfizer INC. | $13.29 | 2022 | |
| Phathom Pharmaceuticals, INC. | $4.97 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.